A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
Clinical trial NCT06439082 · RECRUITING
Trial details
- NCT number
- NCT06439082
- Sponsor
- Novartis Pharmaceuticals
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-10-24
- Primary completion
- 2029-07-02
- Enrollment
- 354
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.